Search

News Less Ventricular Arrhythmias and ICD Shocks After Introduction of Sacubitril/Valsartan

Is the decrease in the incidence of sudden cardiac death among patients using sacubitril/valsartan due to a lower risk of ventricular arrhythmias? And does it have anything to do with reverse left ventricular remodeling? A newly published study utilizing data from telemonitoring of patients with implanted devices focused on this.

Source: Chronic Heart Failure and Lipidology 8. 1. 2020

News LDL cholesterol: a new risk factor for the onset of venous thromboembolic disease?

Not only do atherosclerotic plaques in the arteries and the risk of heart attack decrease along with LDL cholesterol levels. Results from a large molecular genetic study suggest that lowering its levels might also reduce the risk of venous thromboembolic disease.

Source: Cardiovascular Risks 3. 2. 2020

News Relationship Between Mortality and Use of Statins or RAAS Inhibitors After Aortic Valve Replacement

The impact of prescribed medication after transcatheter aortic valve replacement (TAVR) has not been precisely assessed to date. A recently published retrospective analysis of clinical practice data from patients who underwent TAVR aimed to assess the potential benefit of using statins and renin-angiotensin-aldosterone system (RAAS) inhibitors.

Source: Sartans in the Treatment of Hypertension 16. 3. 2023

News Genetic Profiling Transforms the Diagnosis and Treatment of Cancer Diseases

Genome sequencing provides doctors with more information about the causes of cancer diseases and changes the ways of treating tumors. Targeted therapy aimed at oncogenic mutations has brought patients longer survival and better clinical outcomes. Let's take a closer look at the advances and challenges of using genomics in oncology.

Source: Genetic Profile and Treatment of NSCLC 11. 11. 2021

News Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation –⁠ Case Study

Non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease. Individualization of therapy based on the presence of specific tumor cell mutations is therefore crucial for choosing the optimal therapy for these patients. One of the targeted treatment options for patients with NSCLC with an activating mutation in the epidermal growth factor receptor (EGFR) gene is osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI). We present a case study of a patient with NSCLC treated with osimertinib after disease progression due to a secondary EGFR T790M mutation resulting from afatinib therapy. The described case well illustrates the role of osimertinib in the treatment of NSCLC with secondary EGFR T790M mutation.

Source: Lung Cancer 10. 6. 2020

News Subcutaneous zilucoplan –⁠ the end of necessary “trips” to the hospital for myasthenia gravis patients?

A study recently published in Lancet Neurology demonstrated the efficacy and safety of the subcutaneously administered complement component C5 inhibitor –⁠ zilucoplan –⁠ in the treatment of myasthenia gravis (MG). This drug has the potential to alleviate the severity of this disease and improve the quality of life of patients.

Source: Rare Diseases in Neurology 3. 4. 2024

News Is Six Months of Adjuvant Targeted Therapy Sufficient for Early Breast Cancer?

The inclusion of adjuvant targeted therapy with chemotherapy for early HER2-positive breast cancer significantly improved patient outcomes. Since 2006, based on data from registration studies, the gold standard for adjuvant therapy has been 12 months of trastuzumab administration. However, similar effects were observed in a smaller study with just 9 weeks of treatment. The presented clinical trial therefore investigated the non-inferiority of shorter treatment duration (6 months).

Source: Breast Carcinoma 23. 11. 2020

News New Technology Teaches Healthcare Professionals to Deliver Messages Patients Don't Want to Hear

Communication with patients and their relatives is often very challenging for doctors and nurses, especially when the patient or their family member is experiencing strong emotions. A new technology from the startup ComGuide is here to help healthcare professionals practice how to communicate most effectively. Jan Hrdlička, the co-author, explained how exactly this technology works, who it is suitable for, and how it was developed and continues to evolve.

Source: 3. 5. 2024

News Treatment Options for Advanced Parkinson's Disease Using Medical Devices (DAT)

A new treatment option for advanced Parkinson's disease (PD) using medical devices (DAT −⁠ device-aided therapy) is the intestinal infusion gel containing levodopa, entacapone, and carbidopa (LECIG). An article published in 2022 in the journal Therapeutic Advances in Neurological Disorders provides an overview of current DAT modalities in PD patients and presents LECIG as the latest extension of options in this area.

Source: Parkinson's Disease 14. 9. 2023

News Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors

Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the 2nd line after progression on a 1st-generation ALK inhibitor, crizotinib. American scientists in a phase II study focused on the efficacy of brigatinib in the treatment of patients with advanced NSCLC who had progressed on 2nd-generation ALK inhibitors.

Source: Non-Small Cell Lung Cancer 15. 2. 2021

News Combination of Candesartan with ACE Inhibitors in the Treatment of Hypertension and Heart Failure

Although the combination of ACE inhibitors and sartans is not recommended due to the higher incidence of complications, studies also indicate a positive effect of their concurrent administration. The potential use of dual blockade of the renin-angiotensin-aldosterone system (RAAS) is suggested in resistant hypertension, and results have also been described in the treatment of congestive heart failure. What do the recommendations say?

Source: Sartans in the Treatment of Hypertension 25. 5. 2020

Články časopisu Von Willebrand disease

Author of the article: P. Smejkal, M. Matýšková, M. Penka Source: Vnitřní lékařství | 3/2008 9. 3. 2008

News Benefit of Maintenance Therapy with Olaparib in Newly Diagnosed Advanced Ovarian Cancer

The SOLO-1 study evaluated whether the use of the PARP inhibitor olaparib in the maintenance treatment of patients with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer with BRCA 1/2 mutation leads to an improved prognosis for these patients.

Source: Ovarian and Breast Cancer 17. 3. 2020

News Effectiveness of Dietary Intervention in Irritable Bowel Syndrome –⁠ Results of a Network Meta-Analysis

A low FODMAP diet is often recommended to alleviate symptoms of irritable bowel syndrome (IBS). Although several randomized studies have been conducted to assess the effectiveness of this diet, a systematic evaluation has yet to be available, and individual studies have used various control interventions. Therefore, an international team of researchers decided to prepare a systematic literature review with a network analysis, recently published in the journal Gut.

Source: Irritable Bowel Syndrome 12. 10. 2022

News Do Asthma Bronchiale and COPD Represent a Risk Factor for Severe COVID-19 and Death?

It is well known that patients with bronchial asthma and chronic obstructive pulmonary disease (COPD) have a higher risk of severe course of common viral respiratory diseases. A study by Belgian authors involving several hundred individuals evaluated the risk of ICU admission and death due to COVID-19 in patients with asthma and COPD compared to patients without these conditions. The other goal was to determine whether these risks are influenced by inhalation corticosteroid therapy or not.

Source: Treatment of Asthma and COPD 8. 11. 2021